Stock listing

Synact Pharma Ab

Selected listing: A2ALUN · LSX · EUR · DE

Synact Pharma Ab (LS Exchange: A2ALUN), Health Technology. Latest release Sep 22, 2026: SynAct Pharma to Participate in Investor and Partnering Conferences.

A2ALUN:LSXEURDEUpdated October 3, 2026

Ticker: LS Exchange: A2ALUN
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: LS Exchange
Currency: EUR

About Synact Pharma Ab

The company focuses on developing innovative therapies for inflammatory diseases. Its commitment to advancing healthcare solutions positions it as a notable player in the pharmaceutical industry.

Latest news from Synact Pharma Ab

SynAct Pharma to Participate in Investor and Partnering Conferences

September 22, 2026

WHO Identifies Resomelagon as One Of Six Dengue Drug Candidates with Evidence Supporting Further Clinical Development

September 16, 2026

Further Analysis of the Phase 2b ADVANCE Study Reinforces Phase 2b EXPAND Results and Supports Phase 3 Development - FDA Discussions on Trial Design Planned for Q4 2026

September 7, 2026

SynAct Pharma's CEO and CSO Sell Shares

September 3, 2026

SynAct Pharma publishes Q2 2026 interim results

August 20, 2026

All Synact Pharma Ab news →

Research Synact Pharma Ab

Synact Pharma Ab company profile

View the public company page for Synact Pharma Ab on 6ix.

Synact Pharma Ab news

Read company news and market updates connected to Synact Pharma Ab.

Synact Pharma Ab investor events

Find investor webinars, events, and replay context for Synact Pharma Ab.